ClinicalTrials.Veeva

Menu

Validation of Continuous Monitoring of Vital Signs in Children With a Connected Patch (VITALPICU)

S

St. Justine's Hospital

Status

Enrolling

Conditions

Vital Signs

Treatments

Device: Monitoring with VT-Patch (Connected device manufactured by VitalTracer)

Study type

Interventional

Funder types

Other

Identifiers

NCT04627766
2021-3157

Details and patient eligibility

About

Small connected devices monitoring vital signs do not exist in children although they could be very useful to monitor patients once they have left the pediatric intensive care unit (PICU) in order to early identify patients at risk of PICU readmission.

The main objective of this study is to assess the accuracy of a connected thoracic patch (VT-Patch) for the continuous monitoring of vital signs in PICU patients.

This monitoring device will be used to monitor children in PICU for 8 hours and results will be compared to the standard of care in the unit which is the Philips monitoring system.

The investigators will assess the device's accuracy for the monitoring of 4 vital signs (SpO2, heart rate, respiratory rate and temperature) and perform exploratory assessment of three additional parameters (EKG, blood pressure and movement capture). The skin colour of each participant will be categorized based on Fitzpatrick scale and non-invasive spectroscopic method.

Full description

Introduction:

Patients readmission to PICU is a major point of concern for physician because, although being a rare event, it has been strongly associated to more morbidity and death. Patients monitoring once they have left the PICU is drastically modified and small connected devices could be an option to early identify patients at risk of PICU readmission. Such devices have been manufactured for the monitoring of adults but they do not exist for children.

Besides, studies have recently shown that devices that use optical sensors may be less accurate in individuals with dark skin pigmentation since dark skin tones impose a limitation on optical biometric sensing. The wearable and medical device industry has not sufficiently addressed this issue yet. This is one of the main challenges that need to be addressed in this area to make sure the connected devices using this technology will work with all different skin colours including very dark skin.

Main objective:

Assess the accuracy of VT-Patch to measure oxygen saturation (SpO2) in children with diverse skin colour.

Secondary objectives:

Assess the accuracy of VT-Patch monitoring for 3 additional physiologic parameters (heart rate (HR), respiratory rate (RR) and temperature). Exploratory assessment of blood pressure (BP) monitoring, ECG signal and movement capture. The effect of the skin colour on the vital signs measurements will be investigated as well.

Design:

Prospective validation study of VT-Patch device for the monitoring of 4 physiologic parameters and exploratory assessment of three additional parameters.

Methods:

The study will be performed in two successive phases:

  • Run-in phase: testing the device on 5 children to assess the feasibility of the protocol.

  • Main study: validation phase of the device on 2 children per age group per skin phototype (based on Monk scale) to assess its accuracy. The patients of the run-in phase will be included in the main study if no modification of the protocol is required.

    4 physiologic parameters (HR, SpO2, RR, temperature and BP) and ECG will be prospectively recorded during 8 hours with VT-Patch and the regular monitoring system implemented in the unit High-resolution database that will be the Gold standard for evaluation.

Participating center: 1 center (St. Justine's Hospital).

Perspectives: This validation step of the collected data is necessary to validate that VT-Patch is suitable for pediatric patient monitoring of all skin colors.

Enrollment

48 estimated patients

Sex

All

Ages

Under 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Children (0 to 18 years old) admitted in St. Justine's Hospital's PICU.
  • PICU monitoring for the next 24 hours

Exclusion criteria

  • Recent cardiac or thoracic surgery
  • Thoracic skin lesion that contraindicates the VT-Patch
  • No parental consent
  • Intermittent presence of one study observer in the patient room is considered inappropriate by the physician or the nurse in charge because of the child's medical condition

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

48 participants in 1 patient group

Monitored children
Experimental group
Description:
PICU Children that will be monitored with the device
Treatment:
Device: Monitoring with VT-Patch (Connected device manufactured by VitalTracer)

Trial contacts and locations

1

Loading...

Central trial contact

Philippe Jouvet, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems